INTRODUCTION
============

Tuberculosis (TB) is one of the most important issues of public health worldwide. About one third of the world population has been infected with *M. tuberculosis*, over 8.7 million new cases and 1.4 million deaths each year [@B1]. The current efforts to reduce the global problem have been focused on improving the diagnosis methods and effective vaccines. The biochemical, immunological, and molecular biological characteristics of *M. tuberculosis* have led to the identification of several antigens which may be useful in the development of improved diagnostic methods and/or vaccines [@B2].

In 2010, Inaki Comas et al reported that human T cell epitopes of *M. tuberculosis* were evolutionarily hyperconserved and thus deduced that *M. tuberculosis* was lack of antigenic variation and immune evasion [@B3]. However, our previous studies showed that there were polymorphisms existing in two important antigens, MPT64 [@B4] and PstS1 [@B5] in clinical *M. tuberculosis* strains isolated from China. This may be the reason for changes in the antigens produced, which may in turn cause alteration of related functions, thereby allowing immune evasion. Some other proteins such as Rv2945c and Rv0309 also owned polymorphisms, which suggest their roles in diversifying selection to evade host immunity [@B6]. The antigen 85 complex (Ag85) consists of three predominantly secreted proteins (Ag85A, Ag85B, and Ag85C), which plays a key role in the mycobacterial pathogenesis and also possesses enzymatic mycolyltransferase activity involved in cell wall synthesis [@B7]. Disruption of the gene encoding Ag85A in *M. tuberculosis* produces a strain that fails to replicate in human or mouse macrophages indicating that Ag85A may play a key role in *M.tuberculosis* pathogenesis. Knockout of the gene encoding Ag85C results in 40% reduction of *M.tuberculosis* the cell wall mycoloylation. Ag85 complex contribute to adherence, invasion, and dissemination of mycobacteria in host cells [@B8]. By virtue of their strong potential to induce Th1-type immune responses, important for the control of intracellular infections, Mycobacterium Ag85 complex rank among the most promising TB vaccine candidate antigens. [@B9]-[@B14]. Recently, Modified-Vaccinia-Ankara (MVA)85A vaccine became the first TB vaccine since BCG itself to complete an efficacy trial [@B15].

Here, we used the same set of clinical *M. tuberculosis* complex (MTBC) isolates(including two BCG strains) from China in our previous study [@B4], amplified genes of the antigens Ag85 (Ag85A, Ag85B, and Ag85C) and compared the sequences to explore the genetic diversity of them and to evaluate the impact of immune recognition on sequence variation of these three genes. In addition, we analyzed changes in protein level which was induced by single nucleotide polymorphism in Ag85 genes.

MATERIALS AND METHODS
=====================

Strains and DNA preparation
---------------------------

The first set of strains consisted of 180 clinical isolates that were selected from 2346 MTBC strains isolated in China genotyped by spoligotyping previously [@B16]. All major and rare genotyping strains in China were included (Table [1](#T1){ref-type="table"}). Considering the predominance of the Beijing family strains in China, we chose about half of the Beijing family strains (92 strains) and half non-Beijing family strains (88 strains). We randomly selected the 92 Beijing family strains from 1738 Beijing strains among 2346 strains. The other 88 strains were selected from 608 non-Beijing family isolates. Further, we attempted to purposely include strains representing different spoligotypes that were isolated from different regions. Table [2](#T2){ref-type="table"} showed the numbers of strains used in this study that were obtained from different provinces in China. A second set of strains contained 11 BCG strains, each of which originated from different places around the world. The strain names were showed in Table [3](#T3){ref-type="table"}.

These strains were cultured using the standard Löwenstein-Jensen medium method, the genomic DNA were prepared according to previously reported and then used directly in polymerase chain reactions (PCRs).

The following Ag85 genes of the four published *M.bovis* and BCG strains were obtained from the NCBI genome website: *M. bovis* AF2122/97 (NC_002945), BCG Pasteur 1173P2 (NC_008769), BCG Tokyo 172 (NC_012207) and BCG Mexico (NC_016804).

Primers
-------

The nucleotide sequences of the primers (from the 5\' to 3\' end) used in this study were designed with DNAstar software according to H37Rv genome sequence and showed in Table [4](#T4){ref-type="table"}.

Polymerase Chain Reaction
-------------------------

The PCR were performed in a total volume of 20μl. The PCR mix contained 10μl PCR buffer, 100nM each primer, 200μM each of the four dNTPs and 0.5U DNA Taq Polymerase (Takara). An initial denaturation of 5min at 94℃ was followed by 35 cycles of denaturation at 94℃ for 45s, annealing at 62℃ for 45s and extension at 72℃ for 1min, followed by a final extension at 72℃ for 10min.

Negative controls using ddH~2~O instead of DNA were included each time when the PCR was performed. The positive control was 500pg DNA from *M. tuberculosis* H37Rv. The presence and size of each PCR product were determined by electrophoresis on 2% agarose gel in Tris/boric acid/EDTA buffer followed by staining with ethidium bromide.

We performed all of the PCRs at least twice to validate the reproducibility. The variants were confirmed by sequencing of the new PCR products.

Sequence and data Analysis
--------------------------

The sequences of the PCR products were determined by ABI 3730xl DNA Analyzer.

The sequences were first aligned by ClustalW [@B17] software with the *Ag85* genes sequence from *M. tuberculosis* H37Rv genome to determine the regions of the genes, and then these regions were split out by a personalized PERL script. The sequence compare and translation were carried out by Bioedit software. Values of dN and dS were calculated by MEGA5. In addition, SPSS 14.0 (SPSS, Inc.) was used to perform chi-square analysis, and differences were considered to be statistically significant when *P*\<0.05.

RESULTS
=======

Mutations in gene sequences of Ag85
-----------------------------------

All 180 strains presented relative PCR products of antigens Ag85A, Ag85B and Ag85C. Table [5](#T5){ref-type="table"} showed the mutations in the gene sequences of Ag85A, Ag85B and Ag85C. Ag85A harbored three nonsynonymous mutations and two synonymous mutations. Ag85B owned two nonsynonymous mutations and three synonymous mutations. There were one nonsynonymous mutation and one synonymous mutation in antigen Ag85C.

A total of 16 BCG strains (14 different BCG strains described above and 2 BCG strains from the clinical sample in China in the first isolates set) and one M.bovis (M. bovis AF2122/97, NC_002945) were included in this study. All of the *M.bovis* and BCG strains had two unique SNPs located in C935G of Ag85A and T418C of Ag85B. In the gene sequence of Ag85B, position 714 presented higher polymorphisms, as 93 strains owned an sSNPs (C-A). Six strains, i.e. four CAS family strains, one Beijing strain and one New strain presented same nonsynonymous mutation (G472A) in gene sequence of antigen Ag85C.

Changes in T/B cell epitopes
----------------------------

Table [6](#T6){ref-type="table"} presented T cell epitopes and B cell epitopes in Ag85A, Ag85B and Ag85C according to the Immune Epitopes Database (IEDB) [@B18]. In the IEDB database, the impact on immune recognition was tested by bioinformatic approaches, and not in vivo or in vitro. Ag85A and Ag85B owned both T cell epitopes and B cell epitopes, while Ag85C only had three T cell epitopes (See Figure [1](#F1){ref-type="fig"}). For Ag85A and Ag85B, some epitopes were both T cell epitopes and B cell epitopes. Among all of the strains in this study, 12 of 64 T cell epitopes accounting for 18.75% and one of seven B cell epitopes accounting for 14.29% in Ag85A showed AA changes resulting from nucleotide alterations. Ag85B owned 37 B cell epitopes and 54 T cell epitopes, while 23 of them are both. Three B cell epitopes and three T cell epitopes altered from AA changes in Ag85B. There was no change in T cell epitopes of Ag85C.

dN/dS values of proteins, epitope region and non-epitope region
---------------------------------------------------------------

Table [7](#T7){ref-type="table"} showed the distribution of synonymous and nonsynonymous SNPs in Ag85A, Ag85B and Ag85C among all 180 strains. The dN/dS value of Ag85A and Ag85B were 0.23 and 0.021, both much lower than 1, suggesting that these two proteins are likely appeared to be under purifying selection (Form of natural selection that acts to eliminate selectively deleterious mutations). For Ag85A, T/B cell epitope regions harbored higher dN/dS values than non-epitope regions, which mean the formers had accumulated significantly more amino acid changes than the latters. For Ag85B, non-T-cell-epitope regions had higher dN/dS value than T cell epitope regions, while B cell epitope regions owned higher dN/dS than non-B-cell-epitope regions. dN/dS of Ag85C was 2.04, higher than 1. All changes in Ag85C were from non epitope regions.

Changes in protein level
------------------------

All of the *M.bovis* and BCG strains presented two unique mutations in A312G of Ag85A and F140L of Ag85B, which might represent special mutations in BCG strains. Six strains with mutation of G158S in Ag85C included four CAS strains (XZ06003, XJ06018, XJ06153 and XJ06188), one Beijing strain (FJ06159) and one new spoligotype strain (FJ05009). As the C714A in *Ag85B* showed high polymorphism, we counted the frequencies of the synonymous mutation (Table [7](#T7){ref-type="table"}). Among the 92 isolates of Beijing genotype, 95 % (n = 87) of the isolates presented A; meanwhile, among the 88 non-Beijing isolates, only ten isolates were A in the position 714 of *Ag85B*.

DISCUSSION
==========

In this study, we chose 180 clinical MTBC strains which were originated from a very large geographical area and have different spoligotyping patterns in China; hence the data provided by them could be representative of genetic diversity that might be present within China, at least to some extent.

Studies in human pathogenic viruses, bacteria and protozoa have revealed that genes encoding antigens tend to be highly variable as a consequence of diversifying selection to evade host immunity [@B19]-[@B22]. Comas et al reported that human T cell epitopes of *M. tuberculosis*were evolutionarily hyperconserved and thus deduced that*M. tuberculosis* was lack of antigenic variation and immune evasion[@B3]. However, in our previous studies, some proteins, such as MPT64, PstS1, Rv0309 and Rv2945c, harbored higher numbers of amino acid substitutions in their T cell epitopes, which suggesting their role in ongoing immune evasion [@B4],[@B5],[@B6]. In this study, we found that Ag85A, Ag85B and Ag85C on the contrary showed lower substitution of amino acid in T/B cell epitopes. The dN/dS value of Ag85A and Ag85B were 0.23 and 0.021, both lower than 1, suggesting that these two proteins were likely appeared to be under purifying selection. dN/dS of Ag85C was 2.04, higher than 1. Yet all changes in Ag85C were from non epitope regions. Our data indicated that Ag85 were hyperconserved in T/B cell epitopes and the genes were more likely to be under purifying selection, which is in line with Comas\' study.

Mycobacterium Ag85 complex consists of Ag85A, Ag85B, and Ag85C, which play an important role in cell wall biosynthesis by catalyzing the synthesis of the cord factor (trehalose 6,6′-dimycolate, TDM) by mycolyltransferase activity and serve as fibronectin-binding proteins that interact with host macrophage to trigger host immune response[@B23],[@B24]. *M. tuberculosis* secretes many proteins into the extracellular environment, which can be recognized by the host immune system and induce protective immunity and immune responses with diagnostic values. Our findings that Ag85 complex are highly conserved in T/B cell epitopes also indicate they are suitable for diagnose and vaccine for TB. Currently, there are several vaccine candidates undergoing clinical trials that represent vaccines with different immune profiles and modes of action. In a study, 2797 BCG-vaccinated infants were boosted with MVA expressing the MTB antigen 85A or a placebo control and thereafter followed for 3 years. However, the outcome of the trial was very disappointing with no detectable improvement of protection against TB [@B15]. It was proposed that rather than boosting Th1 responses, we should focus on understanding protective immune responses that are lacking or insufficiently promoted by BCG that can intervene at critical stages of the TB life cycle [@B25].

Backus KM et al reported that the three *Mycobacterium tuberculosis* antigen 85 isoforms have unique substrates and activities determined by non-active site regions, which reflect the differences among the three antigens [@B26]. Our study showed that each of these three antigens was conserved, suggesting similar activity and substrate selectivity among different strains.

Genes in *M. tuberculosis* was assigned functional categories according to Tuberculist (<http://tuberculist.epfl.ch/>). MPT64, PstS1, Rv2945c and Rv0309 all belong to virulence, detoxification, adaption proteins, while Ag85 are lipid metabolism proteins. Different functions between individual genes indicate they are under distinct selection pressures. The former category of proteins are the first proteins interact with host immune system after *M. tuberculosis* strains infected, which made them easier to be under host immune selection to induce immune evasion. However, Ag85 showed lower polymorphisms than the former proteins. The data showed that proteins Ag85 were under purifying selection. We assume that *M. tuberculosis*proteins in different categories are suffered divergence from host immune selection. More proteins should be included to clarify this point.

In position 312 of Ag85A, a nonpolar amino acid Ala was substituted by a polar one (Gly) in *M.bovis* and BCG strains, the hydrophilicity increased, which suggests that the protein is more likely to combine the membrane structures related to function. The mutation in F140L of Ag85B rarely affects antigen function since it was changed between two nonpolar amino acids, it could still be used as a good phylogenetic marker to differentiate *M.bovis* and BCG strains from *M.tuberculosis* strains. Six strains with mutation of G472A in Ag85C included four CAS strains (XZ06003, XJ06018, XJ06153 and XJ06188), one Beijing strain (FJ06159) and one new spoligotype strain (FJ05009). Therefore, the SNPs were acting as phylogenetic markers for the four CAS strains. For strains in different spoligotypes, i.e. non-closely related strains, we had one homoplastic SNP(convergent evolution), which usually is a strong indicator of selection. As the mutation were changed between two polar amino acids (G-A), it nearly did not affect the protein function. 95 % Beijing isolates presented A in position 714 of *Ag85B*, thus C714A in *Ag85B* seemed to be a valuable phylogenetic marker for Beijing strains.

In conclusion, proteins Ag85 are highly conserved in T/B cell epitopes and the genes are more likely to be under purifying selection. The divergence of host immune selection on different proteins may result from different function of the proteins. A312G of Ag85A and T418C of Ag85B may represent special mutations in BCG strains, which may be used to differentiate *M.bovis* and BCG strains from MTB strains.
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###### 

No. of the strains of each Spoligotype pattern

  Spoligotyping   No. of strains
  --------------- ----------------
  Beijing         92
  T               13
  U               28
  MANU            11
  Haarlem         5
  EAI             1
  LAM             2
  H37Rv family    1
  BCG             2
  S               1
  CAS             4
  new             20

###### 

No. of the strains of different provinces in China

  Places                              No. of isolates
  ----------------------------------- -----------------
  Anhui Province                      12
  Shannxi Province                    17
  Beijing Municipality                11
  Fujian Province                     29
  Gansu Province                      12
  Guangxi Zhuang Autonomous Region    29
  Sichuan Province                    1
  Henan Province                      12
  Hunan Province                      7
  Xizang (Tibet) Autonomous Region,   11
  Xinjiang Uygur Autonomous Region    13
  Jilin Province                      14
  Zhejiang Province                   12

###### 

Strains of *Mycobacterium bovis* and Bacillus Calmette Guerin (BCG).

  ID No.   Strain name
  -------- ------------------------
  1        BCG Birkhaug
  2        BCG China
  3        BCG Danish
  4        BCG Frappier
  5        BCG Glaxo
  6        BCG Moreau
  7        BCG Phipps
  8        BCG Prague
  9        BCG Swedens
  10       BCG Tice
  11       BCG Russia
  12       BCG Tokyo\*
  13       BCG Paster\*
  14       BCG Mexco\*
  15       *M. bovis* AF2122/97\*

\* Data were obtained from the NCBI genome website

###### 

The primers used in this study for PCR amplification

  Gene    Locus tag   Length(bp)   Primers
  ------- ----------- ------------ ---------------------------------
  Ag85A   Rv3804c     1166         5\'- CACCGCCGCTAGATGTTGTG-3\'F
                                   5\'- CGCCCGAAGTTGTGGTTGAC-3\'R
  Ag85B   Rv1886c     1234         5\'- ACTCGGCTAACTGGCTGGT-3\'F
                                   5\'- CGGTAACCGATACGGAAATG -3\'R
  Ag85C   Rv0129c     1509         5\'- TGGTCGGCAGTAAGCATAGG-3\'F
                                   5\'- ACTGGTTGGGAGCGGCC -3\'R

###### 

Changes in antigen Ag85A, Ag85B and Ag85C among 180 clinical strains\*

  -------------------------------------------------------------
  Genes   Isolates     Base change   AA change   Spoligotypes
  ------- ------------ ------------- ----------- --------------
  Ag85A   FJ05009      T12C          No change   New

          FJ06038\     C139T\        P47S\       Haarlem\
          ShanX05098   G141C         No change   Beijing

          HuN06009     C734G         A245G       Beijing

          FJ07113      C935G         A312G       BCG

          JL06005                                

  Ag85B   AH03031      C131T         P44L        Beijing

          FJ07113      T418C         F140L       BCG

          JL06005                                

          GS05127      C666T         No change   Beijing

          GS05129                                

          93 strains   C714A         No change   -\#

          AH03037      C786G         No change   Beijing

  Ag85C   JL06007      G420A         No change   Beijing

          FJ05009      G472A         G158S       New

          FJ06159      Beijing                   

          XZ06003      CAS                       

          XJ06018      CAS                       

          XJ06153      CAS                       

          XJ06188      CAS                       
  -------------------------------------------------------------

\*: Use the CDS of Ag85A, Ag85B and Ag85C of *M. tuberculosis* H37Rv strain as the reference sequence.

\#: Details are showed in [Supplementary Material](#SM1){ref-type="supplementary-material"}: Table S1

###### 

Amino acid changes of human T/B cell epitopes in antigen Ag85A, Ag85B and Ag85C^\*,‡^

  -----------------------------------------------------------------------------------------------------------
  T or B epitope   IEDB_ID   Epitope                           Rv locus   Base change   AA change   Antigen
  ---------------- --------- --------------------------------- ---------- ------------- ----------- ---------
  T                56994     SASMGRDIKVQFQG                    Rv0129c    No            No          Ag85C

  T                72965     WPTLIGLAM                         Rv0129c    No            No          Ag85C

  T                74768     YLLDGLRAQ                         Rv0129c    No            No          Ag85C

  B                503       AAVVLPGLVGLAGGAATAGA              Rv1886c    No            No          Ag85B

  B                34776     LAGGAATAGAFSR**[P]{.ul}**GLPVEY   Rv1886c    CCG-TGG       P-W         Ag85B

  B                42790     MTDVSRKIRAWGRRLMIGTA              Rv1886c    No            No          Ag85B

  B                43514     NDPTQQI**[P]{.ul}**KLVANNTRLWVY   Rv1886c    CCC-CCA       No          Ag85B

  B                48646     PNGTHSWEYWGAQ                     Rv1886c    No            No          Ag85B

  B                72515     WGRRLMIGTAAAVVLPGLVG              Rv1886c    No            No          Ag85B

  B                103272    IGLSMAGSSAMILAA                   Rv1886c    No            No          Ag85B

  B                103457    PAEFLENFVRSSNLK                   Rv1886c    No            No          Ag85B

  B                103530    QSGGNNSPAVYLLDG                   Rv1886c    No            No          Ag85B

  B                103532    QSSFYSDWYSPACGK                   Rv1886c    No            No          Ag85B

  B                103578    SAAIGLSMAGSSAMI                   Rv1886c    No            No          Ag85B

  B                103668    TSELPQWLSANRAVK                   Rv1886c    No            No          Ag85B

  B                103729    WG**[P]{.ul}**SSDPAWERNDPT        Rv1886c    CCC-CCT       No          Ag85B

  B                103732    WLSANRAVKPTGSAA                   Rv1886c    No            No          Ag85B

  T                3094      AMGDAGGYK                         Rv1886c    No            No          Ag85B

  T                5623      AVYLLDGLR                         Rv1886c    No            No          Ag85B

  T                8685      DIKVQFQSG                         Rv1886c    No            No          Ag85B

  T                13215     ELPQWLSANR                        Rv1886c    No            No          Ag85B

  T                13473     ENFVRSSNL                         Rv1886c    No            No          Ag85B

  T                15116     EYWGAQLNAMKGDLQSSLGA              Rv1886c    No            No          Ag85B

  T                16332     FIYAGSLSA                         Rv1886c    No            No          Ag85B

  T                16333     FIYAGSLSAL                        Rv1886c    No            No          Ag85B

  T                16924     **[F]{.ul}**LTSELPQW              Rv1886c    TTC-CTC       F-L         Ag85B

  T                18276     FVRSSNLKF                         Rv1886c    No            No          Ag85B

  T                21078     GLPVEYLQV                         Rv1886c    No            No          Ag85B

  T                21275     GMGPSLIGL                         Rv1886c    No            No          Ag85B

  T                21780     GPSLIGLAM                         Rv1886c    No            No          Ag85B

  T                26269     IGLSMAGSSAMILAAY                  Rv1886c    No            No          Ag85B

  T                27786     IPAEFLENF                         Rv1886c    No            No          Ag85B

  T                27901     I**[P]{.ul}**KLVANNT              Rv1886c    CCC-CCA       No          Ag85B

  T                29558     IYAGSLSAL                         Rv1886c    No            No          Ag85B

  T                32213     KLVANNTRL                         Rv1886c    No            No          Ag85B

  T                38049     LMIGTAAAV                         Rv1886c    No            No          Ag85B

  T                42342     MPVGGQSSF                         Rv1886c    No            No          Ag85B

  T                43950     NFVRSSNLKFQDAYNAAGGH              Rv1886c    No            No          Ag85B

  T                49862     PVEYLQVPSPSMGRD                   Rv1886c    No            No          Ag85B

  T                52025     QQFIYAGSLSALLDPSQGM               Rv1886c    No            No          Ag85B

  T                59627     SMAGSSAMI                         Rv1886c    No            No          Ag85B

  T                60262     SPSMGRDIKVQFQS                    Rv1886c    No            No          Ag85B

  T                67695     VANNTRLWVYCGNGT                   Rv1886c    No            No          Ag85B

  T                73306     WYYQSGLSI                         Rv1886c    No            No          Ag85B

  T                76455     YWGAQLNAMKGDLQSSLGAG              Rv1886c    No            No          Ag85B

  T                92817     GLAGGAATA                         Rv1886c    No            No          Ag85B

  T                174019    VEYLQVPSPSMGRDI                   Rv1886c    No            No          Ag85B

  T                174021    VPSPSMGRDIKVQFQ                   Rv1886c    No            No          Ag85B

  T/B              223       AAIGLSMAGSSAMILAAYHP              Rv1886c    No            No          Ag85B

  T/B              1545      AGGYKAADMWG**[P]{.ul}**SSDPAWER   Rv1886c    CCC-CCT       No          Ag85B

  T/B              2695      ALLDPSQGMGPSLIGLAMGD              Rv1886c    No            No          Ag85B

  T/B              3400      ANRAVKPTGSAAIGLSMAGS              Rv1886c    No            No          Ag85B

  T/B              6323      CGNGTPNELGGANIPAEFLE              Rv1886c    No            No          Ag85B

  T/B              8688      DIKVQFQSGGNNSPAVYLLD              Rv1886c    No            No          Ag85B

  T/B              10841     DWYSPACGKAGCQTYKWET**[F]{.ul}**   Rv1886c    TTC-CTC       F-L         Ag85B

  T/B              18700     G**[A]{.ul}**NIPAEFLENFVRSSNLKF   Rv1886c    GCC-GCG       No          Ag85B

  T/B              18898     GCQTYKWET**[F]{.ul}**LTSELPQWLS   Rv1886c    TTC-CTC       F-L         Ag85B

  T/B              21096     GLRAQDDYNGWDINTPAFEW              Rv1886c    No            No          Ag85B

  T/B              21797     G**[P]{.ul}**SSDPAWERNDPTQQIPKL   Rv1886c    CCC-CCT       No          Ag85B

  T/B              40165     LTSELPQWLSANRAVKPTGS              Rv1886c    No            No          Ag85B

  T/B              43332     NAVFNFPPNGTHSWEYWGAQ              Rv1886c    No            No          Ag85B

  T/B              45250     NNSPAVYLLDGLRAQDDYNG              Rv1886c    No            No          Ag85B

  T/B              49421     PSLIGLAMGDAGGYKAADMW              Rv1886c    No            No          Ag85B

  T/B              49872     PVGGQSSFYSDWYSPACGKA              Rv1886c    No            No          Ag85B

  T/B              50442     QDAYNAAGGHNAVFNFPPNG              Rv1886c    No            No          Ag85B

  T/B              52026     QQFIYAGSLSALLDPSQGMG              Rv1886c    No            No          Ag85B

  T/B              56895     SAMILAAYHPQQFIYAGSLS              Rv1886c    No            No          Ag85B

  T/B              64079     THSWEYWGAQLNAMKGDLQS              Rv1886c    No            No          Ag85B

  T/B              67697     VANNTRLWVYCGNGTPNELG              Rv1886c    No            No          Ag85B

  T/B              72314     WDINTPAFEWYYQSGLSIVM              Rv1886c    No            No          Ag85B

  T/B              76584     YYQSGLSIVMPVGGQSSFYS              Rv1886c    No            No          Ag85B

  B                1522      AGGGHNGVFDFPDSG                   Rv3804c    No            No          Ag85A

  B                3402      ANRHVKPTGSAVVGL                   Rv3804c    No            No          Ag85A

  B                49333     PSDLGGNNLPAKFLE                   Rv3804c    No            No          Ag85A

  B                51790     QPACRKAGCQTYKWE                   Rv3804c    No            No          Ag85A

  B                70010     VMPVGGQSSFYSDWY                   Rv3804c    No            No          Ag85A

  T                1546      AGGYKASDMWGPKEDPAWQR              Rv3804c    No            No          Ag85A

  T                3403      ANRHVKPTGSAVVGLSMAAS              Rv3804c    No            No          Ag85A

  T                3422      ANSPALYLLDGLRAQDDFSG              Rv3804c    No            No          Ag85A

  T                6901      CQTYKWETF                         Rv3804c    No            No          Ag85A

  T                8686      DIKVQFQSGGANSPALYLLD              Rv3804c    No            No          Ag85A

  T                10838     DWYQPACGKAGCQTYKWETF              Rv3804c    No            No          Ag85A

  T                18896     GCQTYKWETFLTSELPGWLQ              Rv3804c    No            No          Ag85A

  T                19646     GFVRTSNIKFQDAYNAGGGH              Rv3804c    No            No          Ag85A

  T                20979     GLLDPSQAMGPTLIGLAMGD              Rv3804c    No            No          Ag85A

  T                21093     GLRAQDDFSGWDINTPAFEW              Rv3804c    No            No          Ag85A

  T                21439     GNGKPSDLGGNNLPAKFLEG              Rv3804c    No            No          Ag85A

  T                21482     GNNLPAKFLEGFVRTSNIKF              Rv3804c    No            No          Ag85A

  T                21670     GPKEDPAWQRNDPLLNVGKL              Rv3804c    No            No          Ag85A

  T                21960     GQSSFYSDWY                        Rv3804c    No            No          Ag85A

  T                25363     I**[A]{.ul}**NNTRVWVYCGNGKPSDLG   Rv3804c    GCC-GGC       A-G         Ag85A

  T                31902     KLI**[A]{.ul}**NNTRV              Rv3804c    GCC-GGC       A-G         Ag85A

  T                34823     LAIYHPQQFVYAGAMSGLLD              Rv3804c    No            No          Ag85A

  T                40162     LTSELPGWLQANRHVKPTGS              Rv3804c    No            No          Ag85A

  T                41872     MKPDLQRALGATPNTGPAPQGA            Rv3804c    No            No          Ag85A

  T                43504     NDPLLNVGKLI**[A]{.ul}**NNTRVWVY   Rv3804c    GCC-GGC       A-G         Ag85A

  T                44100     NGVFDFPDSGTHSWEYWG**[A]{.ul}**Q   Rv3804c    GCG-GGG       A-G         Ag85A

  T                49699     PTLIGLAMGDAGGYKASDMW              Rv3804c    No            No          Ag85A

  T                49870     PVGGQSSFYSDWYQPACGKA              Rv3804c    No            No          Ag85A

  T                50444     QDAYNAGGGHNGVFDFPDSG              Rv3804c    No            No          Ag85A

  T                52030     QQFVYAGAMSGLLDPSQAMG              Rv3804c    No            No          Ag85A

  T                52431     QSSFYSDWY                         Rv3804c    No            No          Ag85A

  T                56884     SALTLAIYHPQQFVYAGAMS              Rv3804c    No            No          Ag85A

  T                64081     THSWEYWG**[A]{.ul}**QLNAMKPDLQR   Rv3804c    GCG-GGG       A-G         Ag85A

  T                72312     WDINTPAFEWYDQSGLSVVM              Rv3804c    No            No          Ag85A

  T                73578     YDQSGLSVVMPVGGQSSFYS              Rv3804c    No            No          Ag85A

  T                103416    MQL**[V]{.ul}**DRVRG              Rv3804c    GTT-GTC       No          Ag85A

  T                103423    MSRRLVVGA                         Rv3804c    No            No          Ag85A

  T                173920    AMGPTLIGLAMGDAG                   Rv3804c    No            No          Ag85A

  T                173921    AMSGLLDPSQAMGPT                   Rv3804c    No            No          Ag85A

  T                173924    AYNAGGGHNGVFDFP                   Rv3804c    No            No          Ag85A

  T                173925    DSGTHSWEYWG**[A]{.ul}**QLN        Rv3804c    GCG-GGG       A-G         Ag85A

  T                173926    FEWYDQSGLSVVMPV                   Rv3804c    No            No          Ag85A

  T                173927    FLEGFVRTSNIKFQD                   Rv3804c    No            No          Ag85A

  T                173932    FSGWDINTPAFEWYD                   Rv3804c    No            No          Ag85A

  T                173933    FVYAGAMSGLLDPSQ                   Rv3804c    No            No          Ag85A

  T                173934    FYSDWYQPACGKAGC                   Rv3804c    No            No          Ag85A

  T                173935    G**[A]{.ul}**QLNAMKPDLQRAL        Rv3804c    GCG-GGG       A-G         Ag85A

  T                173936    GGQSSFYSDWYQPAC                   Rv3804c    No            No          Ag85A

  T                173937    GKAGCQTYKWETFLT                   Rv3804c    No            No          Ag85A

  T                173938    GKLI**[A]{.ul}**NNTRVWVYCG        Rv3804c    GCC-GGC       A-G         Ag85A

  T                173941    KEDPAWQRNDPLLNV                   Rv3804c    No            No          Ag85A

  T                173943    KVQFQSGGANSPALY                   Rv3804c    No            No          Ag85A

  T                173944    LLDGLRAQDDFSGWD                   Rv3804c    No            No          Ag85A

  T                173948    MGRDIKVQFQSGGAN                   Rv3804c    No            No          Ag85A

  T                173950    NNTRVWVYCGNGKPS                   Rv3804c    No            No          Ag85A

  T                173953    PLLNVGKLI**[A]{.ul}**NNTRV        Rv3804c    GCC-GGC       A-G         Ag85A

  T                174003    QTYKWETFLTSELPG                   Rv3804c    No            No          Ag85A

  T                174004    RAQDDFSGWDINTPA                   Rv3804c    No            No          Ag85A

  T                174007    SELPGWLQANRHVKP                   Rv3804c    No            No          Ag85A

  T                174010    SPALYLLDGLRAQDD                   Rv3804c    No            No          Ag85A

  T                174014    SWEYWG**[A]{.ul}**QLNAMKPD        Rv3804c    GCG-GGG       A-G         Ag85A

  T                174016    TGSAVVGLSMAASSA                   Rv3804c    No            No          Ag85A

  T                174020    VFDFPDSGTHSWEYW                   Rv3804c    No            No          Ag85A

  T                174022    WLQANRHVKPTGSAV                   Rv3804c    No            No          Ag85A

  T                174023    WQRNDPLLNVGKLI**[A]{.ul}**        Rv3804c    GCC-GGC       A-G         Ag85A

  T                174024    WVYCGNGKPSDLGGN                   Rv3804c    No            No          Ag85A

  T                174025    YHPQQFVYAGAMSGL                   Rv3804c    No            No          Ag85A

  T/B              17838     FSR**[P]{.ul}**GLPVEYLQVPSPSMGR   Rv3804c    CCG-TCG\      P-S\        Ag85A
                                                                          CCG-CCC       No          

  T/B              39011     LQVPSPSMGRDIKVQFQSGG              Rv3804c    No            No          Ag85A
  -----------------------------------------------------------------------------------------------------------

^\*^The CDS of Ag85A, Ag85B and Ag85C of *M. Tuberculosis*H37Rv strain has been used as the reference sequence.

^‡^Bold and underlined AA indicates locations of amino acid changes.

###### 

Distribution of synonymous and nonsynonymous SNPs in gene sequence of Ag85A, Ag85B and Ag85C among 180 strains*\**

  --------------------------------------------------------------------------------------------
  Gene                                Length\   SNPs   dN   dS   dN/dS                 
                                      (bp)                                             
  ------- --------------------------- --------- ------ ---- ---- ---------- ---------- -------
  Ag85A   T cell epitope region       939       3      2    5    0.000032   0.000190   0.17

          Non-T-cell-epitope region   75        0      0    0    0          0          0

          B cell epitope region       315       1      1    2    0.000047   0.000146   0.32

          Non-B-cell-epitope region   699       2      1    3    0.000022   0.000183   0.12

          All                         1014      3      2    5    0.000031   0.000134   0.23

  Ag85B   T cell epitope region       897       1      3    4    0.000034   0.002458   0.014

          Non-T-cell-epitope region   78        1      0    1    0.000219   0          NA

          B cell epitope region       930       2      3    5    0.000049   0.002355   0.021

          Non-B-cell-epitope region   45        0      0    0    0          0          NA

          All                         975       2      3    5    0.000047   0.002230   0.021

  Ag85C   T cell epitope region       96        0      0    0    0          0          0

          Non-T-cell-epitope region   924       1      1    2    0.000122   0.000061   2

          All                         1020      1      1    2    0.000108   0.000053   2.04
  --------------------------------------------------------------------------------------------

\* H37Rv was used as reference to base the change in allele for the SNPs

NA, not applicable
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